Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-06-05
2007-06-05
Parkin, Jeffrey S. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S218100
Reexamination Certificate
active
09826115
ABSTRACT:
The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.
REFERENCES:
patent: 5021347 (1991-06-01), Yasui et al.
patent: 5229293 (1993-07-01), Matsuura et al.
patent: 5494671 (1996-02-01), Lai et al.
patent: 5514375 (1996-05-01), Paoletti et al.
patent: 6136561 (2000-10-01), Ivy et al.
patent: 6165477 (2000-12-01), Ivy et al.
patent: 6258788 (2001-07-01), Schmaljohn
patent: 6455509 (2002-09-01), Kochel et al.
patent: 53133627 (1978-11-01), None
patent: 63105682 (1986-10-01), None
patent: 89025725 (1989-05-01), None
patent: 7265093 (1995-10-01), None
patent: WO 90/01946 (1990-03-01), None
patent: WO 92/02548 (1992-02-01), None
patent: WO 92/03545 (1992-03-01), None
patent: WO 93/06214 (1993-04-01), None
patent: WO 98/37911 (1998-09-01), None
patent: WO 99/06068 (1999-02-01), None
patent: WO 99/63095 (1999-12-01), None
patent: WO 02/072036 (2002-09-01), None
patent: WO 02/083903 (2002-10-01), None
Yasui, K., et al., 1990, “Analysis of Japanese encephalitis (JE) virus genome and implications for recombinant JE vaccine”, Southeast Asian J. Trop. Med. Public Health 21(4):663-669.
Colombage et al., “DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against te Flavivirus, Murray Valley Encephalitis Virus,”Virology250:151-163, 1998.
Konishi et al., “The Anamnestic Neutralizing Antibody Response Is Critical for Protection of Mice from Challenge following Vaccination with a Plasmid Encoding the Japanese Encephalitis Virus Premembrane and Envelope Genes,”J. Virology73(7):5527-5534, Jul. 1999.
Konishi et al., “A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice,”Vaccine18:1133-1139, 2000.
Porter et al., “Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses,”Arch. Virol.143:997-1003, 1998.
Raviprakash et al., “Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein,”Vaccine18:2426-2434, 2000.
Schimaljohn et al., “Naked DNA Vaccines Expressing the prM and E Genes of Russian Spring Summer Encephalitis Virus and Central European Encephalitis Virus Protect Mice from Homologous and Heterologous Challenge,”J. Virology71(12):9563-9569, Dec. 1997.
Wang et al., “Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein,”J. Immunol.167:5273-5277, 2001.
Chang et al., “Recent advancement in flavivirus vaccine development”Expert Rev. Vaccines3(2):199-220, 2004.
Guirakhoo et al., “Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates”J. Virol.74(12):5477-5485, 2000.
Simmons et al., “Short Report: Antibody Responses of Mice Immunized with a Tetravalent Dengue Recombinant Protein Subunit Vaccine”Am. J. Trop. Med. Hyg.65(2):159-161, 2001.
Aberle et al., “A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms,”J. Immunol.163:6756-6761, 1999.
Fonseca et al., “Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice,”Vaccine12:279-285, 1994.
Jacobs et al., “High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model,”J. Virol.66:2086-2095, 1992.
Jacobs, “A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge,”Clinical Science85:117-122, 1993.
Mason et al., “Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1,”Virology161:262-267, 1987.
Monath, “Flaviviruses,”Virology(R.N. Fields, ed.) 763-814, 1990.
Pincus et al., “Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis,”Virology187:290-297, 1992.
Ramelow et al., “Detection of tick-borne encephalitis virus RNA in ticks (Ixodes ricinus) by the polymerase chain reaction,”J. Virological Methods45:115-119, 1993.
Schalich et al., “Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions,”J. Virol.70(7):4549-4557, 1996.
Smithburn et al., “A neurotropic virus isolated from the blood of a native of uganda,”Am. J. Trop. Med.20: 471-492, 1940.
Kozak, “An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs,”Nucleic Acids Research, 15(20):8125-8148, 1987.
Chang et al., “Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus,”Virology, 306:170-180, 2003.
Chang et al., “Flavivirus DNA Vaccines,”Annals New York Academy of Sciences, 272-285, 2001.
Davis et al., “West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays,”J. Virology, 75(9):4040-4047, May 2001.
Hunt et al., “A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen,”J. Virological Methods, 97:133-149, 2001.
Abstract, Japanese Patent Publication No. JP 05276941 “Non-infective structure particle preparation, useful as vaccine - by infecting preliminary flavivirus infected cell with cDNA intergrated recombinant vaccinia virus, and then separating non-infective structure particles containing E protein of flavivirus,” (Oct. 26, 1993).
Deubel et al., Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome.Virol.165: 234-244 (1988).
Davis et al., West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-linked Immunosorbent Assays.J. Virol.75(9) : 4040-4047 (2001) (published on-line Apr. 4, 2001).
Konishi et al., Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles.J. Virol.75 (5) : 2204-2212 (2001).
Chang et al., A Single Intramuscular Injectionof Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice.J. Virol.74 (9): 4244-4252 (2000).
Garmendia et al., Recovery and Indentification of West Nile Virus from a Hawk in WinterJ. Clin. Microbiol.38(8) : 3110-3111 (2000).
Johnson et al., Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay.J. Clin. Microbiol.38 (5) : 1827-1831 (2000).
Martin et al., Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assays for Routine Diagnosis of Arboviral Infection.J. Clin. Microbiol.38 (5) : 1823-1826 (2000).
Update: Surveillance for West Nile Virus in Overwintering Mosquitos--- New York, 2000.Morb. Mortal. Wkly. Rep.49(09) : 178
Parkin Jeffrey S.
United States of America as represented by the Secretary of the
LandOfFree
Nucleic acid vaccines for prevention of flavivirus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid vaccines for prevention of flavivirus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid vaccines for prevention of flavivirus infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822561